ℹ️
🇬🇧
Search
Search for people relevant for "poly(adp-ribose) polymerase inhibitor"
poly(adp-ribose) polymerase inhibitor
Person
Class
Person
Publication
Programmes
prof. Ing. Vladimír Wsól Ph.D.
Academic staff at Faculty of Pharmacy in Hradec Králové
2 study programmes
14 classes
198 publications
Study programme
programme
Xenobiochemistry and Pathobiochemistry
+1
🇨🇿 PhD. |
Faculty of Pharmacy in Hradec Králové
Classes
class
General Biochemistry
+1
GAF141 |
Faculty of Pharmacy in Hradec Králové
class
Xenobiochemistry
+1
GAF237 |
Faculty of Pharmacy in Hradec Králové
class
Xenobiochemistry - Practical Training
+3
GAF267 |
Faculty of Pharmacy in Hradec Králové
class
Selected Chapters from General Biochemistry
+1
GDEXP04 |
Faculty of Pharmacy in Hradec Králové
class
The Defense of Doctoral Thesis
+1
GDEXPODP1 |
Faculty of Pharmacy in Hradec Králové
class
Xenobiochemistry and Patobiochemistry
+1
GDEXPSDZ1 |
Faculty of Pharmacy in Hradec Králové
Load more classes (4)
Publications
publication
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
2022 |
Faculty of Pharmacy in Hradec Králové
publication
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters
2022 |
Faculty of Pharmacy in Hradec Králové
publication
Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib
2021 |
Faculty of Pharmacy in Hradec Králové
publication
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism
2021 |
Faculty of Pharmacy in Hradec Králové
publication
Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
2020 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
2020 |
Faculty of Pharmacy in Hradec Králové
publication
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
2020 |
Faculty of Pharmacy in Hradec Králové
publication
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
2020 |
Faculty of Pharmacy in Hradec Králové
publication
Initial characterization of human DHRS1 (SDR19C1), a member of the short chain dehydrogenase/reductase superfamily
2019 |
Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
publication
Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters
2019 |
Faculty of Pharmacy in Hradec Králové
Load more publications (188)
Loading network view...